2013
Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer
Handorf E, Crumpler N, Gross L, Giri V. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal Of Genetic Counseling 2013, 23: 371-376. PMID: 24310616, PMCID: PMC4028414, DOI: 10.1007/s10897-013-9672-5.Peer-Reviewed Original ResearchConceptsHOXB13 G84E mutationProstate cancerG84E mutationFamily historyProstate cancer screening programsCancer screening programsProstate cancer screeningProstate cancer riskHigh-risk menMen ages 35HOXB13 G84ECancer screeningExact binomial confidence intervalsMutation carriersScreening programAge 35Cancer riskClinical utilityUnaffected menPrevalence estimatesGenetic testingPrevalenceCancerConfidence intervalsGenetic counselingGenetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men
Hughes L, Ruth K, Rebbeck T, Giri V. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer And Prostatic Diseases 2013, 16: 308-314. PMID: 24061634, PMCID: PMC3865712, DOI: 10.1038/pcan.2013.36.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramAfrican American menHigh-risk menCC/CTProstate cancerCancer diagnosisIL-16Family historyProstate cancer screening strategiesProstate cancer risk assessmentCancer Risk Assessment ProgramIL-16 genotypesLongitudinal screening programCancer screening strategiesProstate cancer screeningTaqMan SNP genotyping assaysProstate cancer developmentPersonalized risk estimatesAfrican AmericansCancer risk assessmentGenetic variantsHazard ratioSNP genotyping assaysCancer screeningScreening program
2010
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.Peer-Reviewed Original ResearchConceptsHigh-risk menPCa diagnosisCaucasian manElevated prostate-specific antigen concentrationPCa screeningProstate Cancer Risk Assessment ProgramProstate-specific antigen concentrationCancer Risk Assessment ProgramProspective screening cohortCancer diagnosisProspective screening programCT/TTSecond-degree relativesAfrican American menTMPRSS2-ERG fusionUnderwent biopsyScreening cohortStudy entryAA menDegree relativesScreening programBRCA1/2 mutationsSelf-identified raceCox modelGene polymorphisms
2008
Substantial family history of prostate cancer in black men recruited for prostate cancer screening
Mastalski K, Coups E, Ruth K, Raysor S, Giri V. Substantial family history of prostate cancer in black men recruited for prostate cancer screening. Cancer 2008, 113: 2559-2564. PMID: 18816608, PMCID: PMC2626163, DOI: 10.1002/cncr.23862.Peer-Reviewed Original ResearchConceptsFH of PCaProstate Cancer Risk Assessment ProgramNational Health Interview SurveyProstate cancerFamily historyBlack menCancer Risk Assessment ProgramMore first-degree relativesSelf-reported family historyMore family historyProstate cancer screeningHigh-risk menMen ages 35First-degree relativesHealth Interview SurveyAge-matched sampleSuboptimal screeningCancer screeningBreast cancerScreening programAge 35Colon cancerPCa screeningRisk assessment programCancer